Screening and identifying natural products with SARS-CoV-2 infection inhibitory activity from medicinal fungi
S
c
r
e
e
n
i
n
g
a
n
d
i
d
e
n
t
i
f
y
i
n
g
n
a
t
u
r
a
l
p
r
o
d
u
c
t
s
w
i
t
h
S
A
R
S
-
C
o
V
-
2
i
n
f
e
c
t
i
o
n
i
n
h
i
b
i
t
o
r
y
a
c
t
i
v
i
t
y
f
r
o
m
m
e
d
i
c
i
n
a
l
f
u
n
g
i
The coronavirus disease of 2019 (COVID-19), a global pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can result in severe health complications. In addition to physical preventative measures, pharmaceutical intervention is also crucial. Numerous natural products from medicinal fungi have shown promise as potential antiviral drugs and may serve as a source of effective components with antiviral activity against SARS-CoV-2 and other coronaviruses. In this study, we developed a workflow that integrates viral infection inhibition assays at both cellular and molecular levels, as well as molecular separation and characterization, to screen and identify natural products with antiviral activity. Using this workflow, we screened 167 extracts extracted from 36 medicinal fungi using optimized extraction methods. We assessed the antiviral effects of these extracts by measuring their ability to inhibit SARS-CoV-2 infection and receptor binding domain - human angiotensin-converting enzyme 2 (RBD-hACE2) binding in vitro. Following charge- and size-based characterization of the active compounds through filtration and chromatographic fractionation, mass spectrometry characterization of the fractionated compounds revealed that the active components are polysaccharides and determined their monosaccharide residue composition. Our findings provide new insights into the antiviral potential of natural products and their screening strategies and may contribute to the development of effective antiviral therapeutics against COVID-19 and other diseases.